Cargando…

Ex vivo enrichment of PRAME antigen‐specific T cells for adoptive immunotherapy using CD137 activation marker selection

OBJECTIVE: Adoptive immunotherapy with ex vivo expanded tumor‐specific T cells has potential as anticancer therapy. Preferentially expressed antigen in melanoma (PRAME) is an attractive target overexpressed in several cancers including melanoma and acute myeloid leukaemia (AML), with low expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Koon H, Gowrishankar, Kavitha, Street, Janine, McGuire, Helen M, Luciani, Fabio, Hughes, Brendan, Singh, Mandeep, Clancy, Leighton E, Gottlieb, David J, Micklethwaite, Kenneth P, Blyth, Emily
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577233/ https://www.ncbi.nlm.nih.gov/pubmed/33101678 http://dx.doi.org/10.1002/cti2.1200

Ejemplares similares

Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant
por: Gottlieb, David Jonathan, et al.
Publicado: (2021)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant
por: Jiang, Wei, et al.
Publicado: (2022)

CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions
por: Bishop, David C., et al.
Publicado: (2020)

Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV‐specific T cells
por: McGuire, Helen M, et al.
Publicado: (2020)

Characterizing piggyBat—a transposase for genetic modification of T cells
por: Sutrave, Gaurav, et al.
Publicado: (2022)

Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy
por: York, Jarrod, et al.
Publicado: (2022)

HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
por: Grillini, Marco, et al.
Publicado: (2022)

The Expansion of the PRAME Gene Family in Eutheria
por: Chang, Ti-Cheng, et al.
Publicado: (2011)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas
por: Bui, Chau M., et al.
Publicado: (2021)

PRAME expression is similar in scar and desmoplastic melanoma
por: Plotzke, Jaclyn M., et al.
Publicado: (2022)

PRAME induces genomic instability in uveal melanoma
por: Kurtenbach, Stefan, et al.
Publicado: (2023)

A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors
por: Gérard, Catherine, et al.
Publicado: (2015)

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the receptor protein of CRL2(Prame) complex
por: Zhang, Wenjuan, et al.
Publicado: (2021)

PRAME expression and promoter hypomethylation in epithelial ovarian cancer
por: Zhang, Wa, et al.
Publicado: (2016)

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock
por: Muto, Yusuke, et al.
Publicado: (2020)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples
por: Ronchi, Andrea, et al.
Publicado: (2022)

PRAME Expression as Helpful Immunohistochemical Marker in Rhabdoid Melanoma
por: Glutsch, Valerie, et al.
Publicado: (2022)

PRAME protein expression in DICER1‐related tumours
por: Thorner, Paul S, et al.
Publicado: (2022)

Genetic mechanism for the loss of PRAME in B cell lymphomas
por: Mraz, Marek
Publicado: (2022)

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
por: van Amerongen, Rosa A., et al.
Publicado: (2023)

PRAME Expression in Mucosal Melanoma of the Head and Neck Region
por: Ricci, Costantino, et al.
Publicado: (2023)

Molecular and clinicopathological implications of PRAME expression in adult glioma
por: Le, Minh-Khang, et al.
Publicado: (2023)

Intrinsic disorder in PRAME and its role in uveal melanoma
por: Antonietti, Michael, et al.
Publicado: (2023)

PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)

Characteristics and Adoption Success of Shelter Dogs Assessed as Resource Guarders
por: McGuire, Betty
Publicado: (2019)

Duplication and positive selection among hominin-specific PRAME genes
por: Birtle, Zoë, et al.
Publicado: (2005)

PRAME Gene Expression in Acute Leukemia and Its Clinical Significance
por: Ding, Kai, et al.
Publicado: (2012)

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
por: Roszik, Jason, et al.
Publicado: (2017)

Genetic mechanism for the loss of PRAME in B cell lymphomas. Reply.
por: Takata, Katsuyoshi, et al.
Publicado: (2022)

Correction: Intrinsic disorder in PRAME and its role in uveal melanoma
por: Antonietti, Michael, et al.
Publicado: (2023)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
por: Xu, Yichi, et al.
Publicado: (2020)

Analyses of Molecular and Histopathologic Features and Expression of PRAME by Immunohistochemistry in Mucosal Melanomas
por: Toyama, Aimi, et al.
Publicado: (2019)

Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
por: Naik, Adviti, et al.
Publicado: (2021)

Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
por: Spel, Lotte, et al.
Publicado: (2015)

PRAME as diagnostic marker and as regulator for cell fate decisions in germ cell cancers
por: Neuhaus, Nina
Publicado: (2016)

Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ctdcdvdtc1nko0pbasfrskibrm